Abstract: Gastric cancer is a common malignant tumor of the digestive system worldwide. Patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer account for approximately 15% to 20% of all patients with gastric cancer. Patients with HER2-positive gastric cancer show a high degree of malignancy and poor prognosis. Medical intervention is the prime mode of treatment for HER2-positive gastric cancer; however, the prognosis is limited. Antibody-drug conjugates (ADCs) are a new class of effective antitumor drugs consisting of monoclonal antibodies tethered to cytotoxic payload drugs via chemical linkers. ADCs have broad clinical application prospects in HER2-positive gastric cancer. A number of ADCs are now widely used in the clinical treatment of HER2-positive gastric cancer. This article focuses on the research progress of ADCs for the treatment of HER2-positive gastric cancer.